Clinical Trial Update: Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 adaptive clinical trial of VX-147 in adults and children with APOL1-mediated proteinuric kidney disease is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Apol1-mediated Kidney Disease

Drugs mentioned

• VX-147 (VX-147)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Proteinuric Kidney Disease | Phase 2, Phase 3 | Status: RECRUITING